Aobiome

AOBiome is a Boston-based biotech company founded with the mission to transform human health by restoring ammonia-oxidizing bacteria (AOB) to the skin. The company's vision is to leverage this novel class of therapeutics to improve skin health, hypertension, and other systemic conditions. AOBiome focuses on developing live topical biotherapeutics specifically designed to treat a broad range of inflammatory skin disorders, aiming to restore immune functionality that has been compromised by modern living.

Notable figures affiliated with AOBiome include its team of leading scientists and researchers in the field of microbiome science. The company has attracted significant investment from prominent biotech investors, enabling it to advance its innovative treatments through late-stage clinical trials. AOBiome's key achievements include the development of a proprietary strain of AOB and the successful demonstration of its efficacy in improving skin health. The overall impact of AOBiome's work lies in its potential to revolutionize the treatment of inflammatory skin conditions and other related health issues by reintroducing beneficial bacteria to the human microbiome.